Novartis works with visual artist Noma Bar and international patient group MDS Alliance to send a message of hope to people living with myelodysplastic syndromes.

John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

One patient’s story reveals the hidden obstacles to better health – and opportunities to help clear them.

Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.

Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

Inspired by Emily Whitehead, along with other early patients treated with CAR-T cell therapy, Novartis embarked on a pioneering journey to reimagine cancer treatment. After 10 years, we continue to relentlessly pursue new science around cell and gene therapies to transform the lives of patients today and in the future.

Sickle cell disease disproportionately affects babies in Africa, but many go undiagnosed due to lack of screening. Newborn screening is needed to save lives and improve care.

What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.